EVALUATION OF BONE METASTASIS OF BREAST CANCER TO LONG OR SHORT BONES, ACCORDING TO MOLECULAR SUBTYPES
RETROSPECTIVE STUDY
Keywords:
Molecular biology, breast cancer, neoplasm metastasisAbstract
Bone is the most frequent site for breast cancer metastasis. Identifying the possible preference of bone metastasis, such as long or short bones, according to molecular subtypes, could alter oncologists approach, paying special attention to these particular group of patients reducing the side effects of the bone metastatic process, involving multidisciplinary team with orthopedists, minimizing possible sequelae of this metastatic process. Detecting different metastatic sites to long or short bones, according to the molecular subtypes and their possible correlation. Fifty-eight patients with only bone metastasis were chosen. The study material was obtained from paraffin embedded primary tumors. Statistical analysis of the data was carried out. The luminal A, luminal B, hybrid luminal, HER2 + and triple-negative / basal-like molecular subtypes were identified. The molecular subtypes compared to the age of bone implants, the distribution of bone implants, and the disease free interval were not statistically significant.
Downloads
References
Piato S, Piato JRM. Doencas da mama. Rio de Janeiro: Revinter; 2006. 312p
Wei B, Wang J, Bourne P, Yang Q, Hicks D, Bu H, et al. Bone metastasis is strongly associated with estrogen receptor-positive/ progesterone receptor-negative breast carcinomas. Hum Pathol. 2008;39(12):1809-15. https://doi.org/10.1016/j.humpath.2008.05.010
Ahn SG, Lee HM, Cho SH, Lee SA, Hwang SH, Jeong J, et al. Prognostic factors for patients with bone-only metastasis in breast cancer. Yonsei Med J. 2013;54(5):1168-77. https://doi.org/10.3349/ymj.2013.54.5.1168
Gerratana L, Fanotto V, Bonotto M, Bolzonello S, Minisini M, Fasola G, et al. Pattern of metastasis and outcome in patients with breast cancer. Clin Exp Metastasis. 2015;32(2):125-33. https://doi.org/10.1007/s10585-015-9697-2
Robison JE, Perreard L, Bernard PS. State of the science: molecular classifications of breast cancer for clinical diagnostics. Clin Biochem. 2004;37(7):572-8. https://doi.org/10.1016/j.clinbiochem.2004.05.002
Faneyte IF, Peterse JL, Van Tinteren H, Pronk C, Bontenbal M, Beex LV, et al. Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res. 2004;10(13):4457-63. https://doi.org/10.1158/1078-0432.CCR- 03-0054
Perou CM, Sorlie T, Eisen MB, Van de Rijn M, Jeffrey SS, Ress CA, et al. Molecular portraits of human breast tumors. Nature. 2000;406(6797):747-52. https://doi.org/10.1038/35021093
Barros ACSD de, Leite KRM. Classificacao molecular dos carcinomas de mama: uma visao contemporanea. Rev Bras Mastologia. 2015;25(4):146-55. https://dx.doi.org/10.5327/Z201500040006RBM
Arpino G, Bardou VV, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6(3):R149-56. https://dx.doi.org/10.1186%2Fbcr767
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134(7);e48-72.
Cheang MC, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol. 2006;24(36):5637-44. https://doi.org/10.1200/JCO.2005.05.4155
Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118-45. https://doi.org/10.1200/JCO.2006.09.2775
Wludarski SCL, Bacchi CE. High concordance of SP3 rabbit monoclonal antibody with FISH to evaluate HER2 in breast carcinoma. Appl Immunohistochem Mol Morphol. 2008;16(5):466-70. http://dx.doi.org/10.1097/PAI.0b013e318162625c
Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736- 50. https://doi.org/10.1093/jnci/djp082
Bhargava RB, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy. Cancer. 2010;116(6):1431-9. https://doi.org/10.1002/cncr.24876
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Paulo Roberto de Andrade Figaro Caldeira, Carlos Augusto Real Martinez, José Roberto Fígaro Caldeira
This work is licensed under a Creative Commons Attribution 4.0 International License.
